Biopharmaceutical company Affinity completes A+ round of financing

It was reported on July 6 that Affinity recently announced that it has completed the A+ round of financing. This is the second round of financing that the company has won the favor of investment institutions after the company completed the A round of financing led by SDIC Ventures in September 2021. billion RMB.

The A+ round of financing was invested by Hongfu Assets and Xingye Guoxin Asset Management. This round of funds will be used to promote the company’s clinical research process for a number of global innovative drugs with tumor microenvironment-specific activation functions, and to accelerate the research and development of the company’s technology platform and early-stage pipeline to meet a large number of unmet clinical needs in the field of tumor therapy. .

Affinity is a clinical-stage biopharmaceutical company focusing on the development of global innovative anticancer drugs. It has the world’s first patented chemical coupling technology and an exclusive coupling Linker, which can upgrade traditional drug innovation to tumor microenvironment delivery and activation of new precision-guided drugs. Affinity uses chemical groups that can be activated in the microenvironment and Linker to block drug activity to achieve the characteristics of drugs that block toxicity in the periphery of tumors and activate them specifically in tumor tissues, solve on-target toxicity, and improve drug efficacy and expand drug use at the same time. Security window.